Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Aims/hypothesis Glucagon-like peptide-1 receptor (GLP-1R) agonists improve glucose control in animals and humans with type 1 diabetes. However, there is little information on the role of the GLP-1R in the immune system. We studied the role of the GLP-1R in immune function in wild-type (WT) and nonobese diabetic (NOD) and Glp1r-/- mice.Methods Glp1r mRNA expression was examined in sorted immune subpopulations by RT-PCR. The effects of GLP-1R activation were assessed on cAMP production and proliferation, migration and survival of primary immune cells from WT and NOD mice. The ability of primary cells from Glp1r-/- mice to proliferate, migrate or survive apoptosis was determined. Immunophenotyping studies were performed to assess the frequency of immune subpopulations in Glp1r-/- mice.Results Ex vivo activation of the GLP-1R resulted in a modest but significant elevation of cAMP in primary thymocytes and splenocytes from both WT and NOD mice. GLP-1R activation did not increase proliferation of primary thymocytes, splenocytes or peripheral lymph node cells. In contrast, Glp1r-/- thymocytes exhibited a hypoproliferative response, whilst peripheral Glp1r-/- lymphocytes were hyperproliferative in response to mitogenic stimulation. Activation or loss of GLP-1R signalling did not modify apoptosis or chemotaxis in primary lymphocytes. Male Glp1r-/- mice exhibited a significantly lower percentage of peripheral regulatory T cells, although no differences were observed in the numbers of CD4+ and CD8+ T cells and B cells in the spleen and lymph nodes of Glp1r-/- mice.Conclusions/interpretation These studies establish that GLP-1R signalling may regulate lymphocyte proliferation and maintenance of peripheral regulatory T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lymphoid cells express Glp1r more often than myeloid cells (35), with tissue-resident lymphocyte subsets showing stronger expression.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745 · cited 1×
“Additionally, we examined splenic CD4+CD25+ cells, at least 75% of which also expressed FOXP3 in independent experiments, and are therefore thought to be Tregs [20].”
Lymphocyte traffic control by chemokines
Moser, B., & Loetscher, P. (2001) · Nature Immunology · doi:10.1038/84219 · Cited by 1,240 · cited 1×
“This result was also unanticipated, as it is well accepted that G protein-coupled receptor signalling is crucial for chemotaxis [49, 50].”
BackgroundDrucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 1×
“Although GLP-1 action was first localised to beta cells [28], the GLP-1R is detected in extrapancreatic tissues, including liver, lung, kidney, heart, brain and intestine [29, 30].”
BackgroundSelf-citationCalcium signaling mechanisms in T lymphocytes.
Lewis, R. S. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.497 · Cited by 860 · cited 1×
“These results might partially explain the hyperresponsiveness of immune cells lacking GLP-1R signalling, as elevation in cytosolic calcium is a triggering signal for lymphocyte proliferation (as reviewed [44]).”
BackgroundTruneh, A., Albert, F., Golstein, P., & Schmitt-Verhulst, A.-M. (1985) · Nature · doi:10.1038/313318a0 · Cited by 746 · cited 1×
“The combination of PMA and ionomycin induces proliferation by directly activating protein kinase C (PKC) and increasing intracellular calcium levels, hence bypassing T cell reception activation [38].”
BackgroundMechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680 · cited 1×
“GLP-1R activation leads to cAMP production in primary immune cells GLP-1R activation is coupled to cAMP accumulation in multiple cell types [ 21 ].”
BackgroundIncretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649 · cited 1×
“GLP-1R agonists and dipeptidyl peptidase-4 inhibitors are approved for the treatment of type 2 diabetes [22] and are being examined in clinical trials of islet transplantation in patients with type 1 diabetes [16, 17], an autoimmune disorder resulting from defective immunoregulation [23, 24].”
BackgroundSelf-citationTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 1×
“Although GLP-1 action was first localised to beta cells [28], the GLP-1R is detected in extrapancreatic tissues, including liver, lung, kidney, heart, brain and intestine [29, 30].”
BackgroundGlucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589 · cited 1×
“In contrast, GLP1R activation inhibits apoptosis in other cell types including islet beta cells, cardiomyocytes and neurons [46–48].”
BackgroundSelf-citationNoyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“In contrast, GLP1R activation inhibits apoptosis in other cell types including islet beta cells, cardiomyocytes and neurons [46–48].”
BackgroundSelf-citationMechanisms of β-Cell Death in Type 2 Diabetes
Donath, M. Y., Ehses, J. A., Maedler, K., Schumann, D. M., Ellingsgaard, H., Eppler, E., & Reinecke, M. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s108 · Cited by 444 · cited 1×
“A subset of patients with type 2 diabetes may also exhibit a dysregulated immune system [25–27].”
BackgroundMechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target
Sojka, D. K., Huang, Y., & Fowell, D. J. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.02813.x · Cited by 393 · cited 1×
“In fact, Tregs express high levels of cAMP, and are able to induce cAMP accumulation in activated target cells by multiple mechanisms [34, 35].”
BackgroundProtection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4
Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380 · cited 1×
“In contrast, GLP1R activation inhibits apoptosis in other cell types including islet beta cells, cardiomyocytes and neurons [46–48].”
BackgroundCampos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353 · cited 1×
“Although GLP-1 action was first localised to beta cells [28], the GLP-1R is detected in extrapancreatic tissues, including liver, lung, kidney, heart, brain and intestine [29, 30].”
BackgroundSelf-citationGlucagon-like peptide-1 prevents beta cell glucolipotoxicity
Joly, E., Prentki, M., Buteau, J., El-Assaad, W., Rhodes, C. J., & Rosenberg, L. (2004) · Diabetologia · doi:10.1007/s00125-004-1379-6 · Cited by 337 · cited 1×
“Potential candidates could be transcription factors, as GLP-1R activation in the islet beta cells has been shown to promote nuclear translocation of nuclear factor kappaB and the nuclear factor of activated T cells, and to activate several immediate earlyresponse genes and proto-oncogenes [39–41], which are common in…”
BackgroundSuarez-Pinzon, W. L., Power, R. F., Yan, Y., Wasserfall, C., Atkinson, M., & Rabinovitch, A. (2008) · Diabetes · doi:10.2337/db08-0688 · Cited by 187 · cited 1×
“The authors observed an induction of suppressive cytokine secretion in islet-infiltrating leucocytes, and concluded that the GLP-1 and gastrin combination therapy may regulate immune pathways in the NOD mice [ 13 ].”
BackgroundSherry, N. A., Chen, W., Kushner, J. A., Glandt, M., Tang, Q., Tsai, S., Santamaria, P., Bluestone, J. A., Brillantes, A.-M. B., & Herold, K. C. (2007) · Endocrinology · doi:10.1210/en.2007-0358 · Cited by 169 · cited 1×
“The regenerative and cytoprotective effects of glucagon-like peptide-1 (GLP-1) on beta cells have engendered considerable interest in whether GLP-1 may be useful for the treatment of type 1 diabetes, either in combination with immunomodulation [3–6] or as adjunctive therapy in islet transplantation [7–10].”
BackgroundPederson, R. A., Satkunarajah, M., McIntosh, C. H., Scrocchi, L. A., Flamez, D., Schuit, F., Drucker, D. J., & Wheeler, M. B. (1998) · Diabetes · doi:10.2337/diabetes.47.7.1046 · Cited by 167 · cited 1×
“Indeed, it was previously reported that glucoregulatory actions of GLP-1 are compensated via other mechanisms in Glp1r �/� mice [ 45 ].”
BackgroundSelf-citationCure of Overt Diabetes in NOD Mice by Transient Treatment With Anti-Lymphocyte Serum and Exendin-4
Ogawa, N., List, J. F., Habener, J. F., & Maki, T. (2004) · Diabetes · doi:10.2337/diabetes.53.7.1700 · Cited by 155 · cited 1×
“The regenerative and cytoprotective effects of glucagon-like peptide-1 (GLP-1) on beta cells have engendered considerable interest in whether GLP-1 may be useful for the treatment of type 1 diabetes, either in combination with immunomodulation [3–6] or as adjunctive therapy in islet transplantation [7–10].”
BackgroundRise and Fall of Cyclic AMP Required for Onset of Lymphocyte DNA Synthesis
Wang, T., Sheppard, J. R., & Foker, J. E. (1978) · Science · doi:10.1126/science.208147 · Cited by 153 · cited 1×
“Stimulation of T cells with ConA is dependent on changes in cellular cAMP [36, 37].”
BackgroundSusini, S., Roche, E., Prentki, M., & Schlegel, W. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.12.1173 · Cited by 137
Susini, S., Roche, E., Prentki, M., & Schlegel, W. (1998) · PubMed · Cited by 133
Effect of Exenatide on ?? Cell Function After Islet Transplantation in Type 1 Diabetes
Ghofaili, K. A., Fung, M., Ao, Z., Meloche, M. R., Shapiro, R. J., Warnock, G. L., Elahi, D., Meneilly, G. S., & Thompson, D. M. (2007) · Transplantation · doi:10.1097/01.tp.0000251379.46596.2d · Cited by 129 · cited 2×
“The use of exenatide therapy in patients with type 1 diabetes [16, 17], despite limited knowledge of the putative immunoregulatory role of the GLP-1R, prompted us to ascertain whether the GLP-1R is active in a range of immune cells.”
BackgroundMacrophages, cytokines and β-cell death in Type 2 diabetes
Ehses, J. A., Böni‐Schnetzler, M., Faulenbach, M. V., & Donath, M. Y. (2008) · Biochemical Society Transactions · doi:10.1042/bst0360340 · Cited by 118
Lawrence, M. C., Bhatt, H. S., & Easom, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.3.691 · Cited by 115 · cited 1×
“Potential candidates could be transcription factors, as GLP-1R activation in the islet beta cells has been shown to promote nuclear translocation of nuclear factor kappaB and the nuclear factor of activated T cells, and to activate several immediate earlyresponse genes and proto-oncogenes [39–41], which are common in…”
BackgroundExendin-4 modulates diabetes onset in nonobese diabetic mice
Hadjiyanni, I., Baggio, L. L., Poussier, P., & Drucker, D. J. (2008) · Endocrinology · doi:10.1210/en.2007-1137 · Cited by 110
Self-citationThe implication of proinflammatory cytokines in type 2 diabetes
Christopher, B. G. (2008) · Frontiers in bioscience · doi:10.2741/3074 · Cited by 109 · cited 1×
“A subset of patients with type 2 diabetes may also exhibit a dysregulated immune system [25–27].”
BackgroundKim, S.-J., Nian, C., Doudet, D. J., & McIntosh, C. H. S. (2009) · Diabetes · doi:10.2337/db08-1101 · Cited by 106 · cited 1×
“In agreement with our results, Kim et al. also did not find a significant effect on migration of GLP-1-treated splenic CD4+ T cells [ 52 ].”
ResultMadsbad, S., Krarup, T., Deacon, C. F., & Holst, J. J. (2008) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328302f414 · Cited by 97 · cited 1×
“Glucagon-like peptide-1 receptor (GLP-1R) activation, either by preventing degradation of its endogenous ligand, or via administration of long-acting receptor agonists, is used for the treatment of type 2 diabetes [1].”
BackgroundHällbrink, M., Holmqvist, T. G., Olsson, M., Östenson, C., Efendić, S., & Langel, Ü. (2001) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(00)00270-3 · Cited by 92
Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment
King, A., Hollister‐Lock, J., Xu, G., Bonner‐Weir, S., & Weir, G. C. (2005) · Diabetologia · doi:10.1007/s00125-005-1922-0 · Cited by 90 · cited 1×
“The regenerative and cytoprotective effects of glucagon-like peptide-1 (GLP-1) on beta cells have engendered considerable interest in whether GLP-1 may be useful for the treatment of type 1 diabetes, either in combination with immunomodulation [3–6] or as adjunctive therapy in islet transplantation [7–10].”
BackgroundFroud, T., Faradji, R. N., Pileggi, A., Messinger, S., Baidal, D. A., Ponte, G., Cure, P., Monroy, K., Mendez, A. J., Selvaggi, G., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e31817c4ab3 · Cited by 83 · cited 2×
“The use of exenatide therapy in patients with type 1 diabetes [16, 17], despite limited knowledge of the putative immunoregulatory role of the GLP-1R, prompted us to ascertain whether the GLP-1R is active in a range of immune cells.”
BackgroundZhang, J., Tokui, Y., Yamagata, K., Kozawa, J., Sayama, K., Iwahashi, H., Okita, K., Miuchi, M., Konya, H., Hamaguchi, T., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0737-6 · Cited by 83 · cited 1×
“Intriguingly, GLP-1R agonists improve type 1 diabetes in animal models without the need for immunotherapy, thus implicating GLP-1R-dependent signalling pathways in immunoregulatory processes [11–14].”
BackgroundIntracellular Signals of T Cell Costimulation
Song, J. J., Lei, F., Xiong, X., & Haque, R. (2008) · Cellular and Molecular Immunology · doi:10.1038/cmi.2008.30 · Cited by 80 · cited 1×
“Potential candidates could be transcription factors, as GLP-1R activation in the islet beta cells has been shown to promote nuclear translocation of nuclear factor kappaB and the nuclear factor of activated T cells, and to activate several immediate earlyresponse genes and proto-oncogenes [39–41], which are common in…”
BackgroundSgouroudis, E., & Piccirillo, C. A. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.945 · Cited by 74 · cited 1×
“Glp1r transcripts were also detected in sorted CD4+ CD25+ cells, a cell subset mostly comprising Tregs [33].”
BackgroundGlycaemic effects of incretins in Type 1 diabetes mellitus
Dupre, J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.003 · Cited by 72 · cited 1×
“GLP-1R activation induces multiple glucoregulatory actions, including inhibition of glucagon secretion and gastric emptying, both of which reduce postprandial glycaemic excursions in patients with type 1 diabetes [2].”
BackgroundIntegrin Regulation by RhoA in Thymocytes
Vielkind, S., Gallagher-Gambarelli, M., Gomez, M., Hinton, H. J., & Cantrell, D. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.1.350 · Cited by 71 · cited 1×
“Transwell migration assays Assays were performed as previously described, with slight modifications [19].”
MethodPoussier, P., Ning, T., Murphy, T., Dabrowski, D., & Ramanathan, S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.4081 · Cited by 67 · cited 1×
“For immunophenotyping and cell-sorting studies, the following monoclonal antibodies were prepared as described previously [18]: purified anti-CD16/CD32 (for Fc blocking), biotinylated anti-CD8α, FITC-labelled antiCD8α, FITC-labelled anti-CD4, phycoerythrin (PE)-labelled anti-CD4, allophycocyanin (APC)-labelled anti-H5…”
MethodFlamez, D., Gilon, P., Moens, K., Van Breusegem, A., Delmeire, D., Scrocchi, L. A., Henquin, J. C., Drucker, D. J., & Schuit, F. (1999) · Diabetes · doi:10.2337/diabetes.48.10.1979 · Cited by 65 · cited 1×
“elevated cytosolic calcium levels, and this increase in calcium was observed at a significantly lower threshold for glucose concentration [43].”
BackgroundSelf-citationImmunology and genetics of type 1 diabetes
Morran, M. P., Omenn, G. S., & Pietropaolo, M. (2008) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20052 · Cited by 64 · cited 1×
“GLP-1R agonists and dipeptidyl peptidase-4 inhibitors are approved for the treatment of type 2 diabetes [22] and are being examined in clinical trials of islet transplantation in patients with type 1 diabetes [16, 17], an autoimmune disorder resulting from defective immunoregulation [23, 24].”
BackgroundTian, B., Hao, J., Zhang, Y., Tian, L., Yi, H., O’Brien, T. D., Sutherland, D. E. R., Hering, B. J., & Guo, Z. (2009) · Transplantation · doi:10.1097/tp.0b013e3181933261 · Cited by 60
Intracellular Signals of T Cell Costimulation
Jian-xun, Сонг, Fengyang, Tylan, Lei, L., Xiaofang, Xiong, Rizwanul, & Haque (2008) · 中国免疫学杂志:英文版 · Cited by 52
Exendin‐4 Therapy in NOD Mice with New‐Onset Diabetes Increases Regulatory T Cell Frequency
Xue, S., Wasserfall, C. H., Parker, M., Brusko, T. M., McGrail, S., McGrail, K., Moore, M., Campbell‐Thompson, M., Schatz, D. A., Atkinson, M. A., et al. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1447.049 · Cited by 51 · cited 4×
“Previous work from our laboratory [12], as well as others [15] suggested that GLP-1R signalling may regulate T cell subsets, including Tregs.”
BackgroundInfluentialCombined treatment with lisofylline and exendin-4 reverses autoimmune diabetes
Yang, Z., Chen, M., Carter, J. D., Nunemaker, C. S., Garmey, J. C., Kimble, S. D., & Nadler, J. L. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.03.177 · Cited by 50 · cited 1×
“The regenerative and cytoprotective effects of glucagon-like peptide-1 (GLP-1) on beta cells have engendered considerable interest in whether GLP-1 may be useful for the treatment of type 1 diabetes, either in combination with immunomodulation [3–6] or as adjunctive therapy in islet transplantation [7–10].”
BackgroundChapter 5 Dysregulation of T Cell Peripheral Tolerance in Type 1 Diabetes
Tisch, R., & Wang, B. (2008) · Advances in immunology · doi:10.1016/s0065-2776(08)00805-5 · Cited by 37
Ivakine, E. A., Fox, C. J., Paterson, A. D., Mortin-Toth, S. M., Canty, A. J., Walton, D. S., Aleksa, K., Ito, S., & Danska, J. S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.7129 · Cited by 33 · cited 1×
“Perhaps not surprisingly there are reported sex-specific patterns of gene expression in the NOD mouse [32].”
BackgroundSelf-citationVendetti, S., Patrizio, M., Riccomi, A., & Magistris, M. T. D. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0106072 · Cited by 27 · cited 1×
“In fact, Tregs express high levels of cAMP, and are able to induce cAMP accumulation in activated target cells by multiple mechanisms [34, 35].”
BackgroundToyoda, K., Okitsu, T., Yamane, S., Uonaga, T., Liu, X.-B., Harada, N., Uemoto, S., Seino, Y., & Inagaki, N. (2008) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2008.01.046 · Cited by 22
Xue, S., Wasserfall, C. H., Parker, M., McGrail, S., MCGRAIL, K. M., Campbell‐Thompson, M., Schatz, D., Atkinson, M. A., & Haller, M. J. (2009) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2008.12.004 · Cited by 20 · cited 1×
“Intriguingly, GLP-1R agonists improve type 1 diabetes in animal models without the need for immunotherapy, thus implicating GLP-1R-dependent signalling pathways in immunoregulatory processes [11–14].”
BackgroundCinalli, R. M., Herman, C. E., Lew, B. O., Wieman, H. L., Thompson, C. B., & Rathmell, J. C. (2005) · European Journal of Immunology · doi:10.1002/eji.200425729 · Cited by 19 · cited 1×
“This result was also unanticipated, as it is well accepted that G protein-coupled receptor signalling is crucial for chemotaxis [49, 50].”
BackgroundJuang, J., Kuo, C., Wu, C.-H., & Juang, C. (2008) · Cell Transplantation · doi:10.3727/096368908786092766 · Cited by 17
Genetic Control of T and B Lymphocyte Activation in Nonobese Diabetic Mice
Chiu, P., Jevnikar, A. M., & Danska, J. S. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.12.7169 · Cited by 17 · cited 1×
“demonstrated a higher frequency of activated B and T cells in the NOD mouse compared with other strains, including the C57BL/6 mouse [31].”
BackgroundSelf-citationMechanisms of lymphocyte “deletion” by high concentrations of ligand
Takigawa, M., & Waksman, B. H. (1981) · Cellular Immunology · doi:10.1016/0008-8749(81)90146-5 · Cited by 14 · cited 1×
“Stimulation of T cells with ConA is dependent on changes in cellular cAMP [36, 37].”
BackgroundDupre, J. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2005.06.012 · Cited by 8
Barbero (2014) · doi:10.1016/j · Cited by 1
Cited by
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“mice, including thymoyctes, splenocytes, bone-marrow-derived cells, and regulatory T cells (Hadjiyanni et al., 2010).”
BackgroundInfluentialSelf-citationThe Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Self-citationThe pathophysiology of hypertension in patients with obesity
DeMarco, V. G., Aroor, A. R., & Sowers, J. R. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.44 · Cited by 545
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
“Its receptor mRNA was discovered in multiple immune cell types from mice, including thymoyctes, splenocytes, bone marrow–derived cells, regulatory T cells, macrophages, and invariant natural killer T cells (Hadjiyanni et al., 2010; Hogan et al., 2011; Panjwani et al., 2013).”
Background
Metadata
- Authors
- Hadjiyanni, I., Siminovitch, K. A., Danska, J. S., & Drucker, D. J.
- Affiliations
- Mount Sinai Hospital (CA)
- University of Toronto (CA)
- Corresponding author
- Drucker, D. J.
- Venue
- Diabetologia
- Published
- 2010-01-08
- Volume
- 53
- Issue
- 4
- Pages
- 730-740
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2036909990
- Cited by
- 166
- References
- 54
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 12 · 2023: 11 · 2022: 12 · 2021: 13 · 2020: 5 · 2019: 9 · 2018: 4 · 2017: 13 · 2016: 7 · 2015: 10 · 2014: 8 · 2013: 11 · 2012: 5
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Canada Research Chairs
- Hospital for Sick Children
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- GLP-1 receptor, lymphocyte proliferation, regulatory T cells, type 1 diabetes, NOD mice, thymocytes, splenocytes, cyclic AMP, apoptosis, chemotaxis
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Cyclic AMP, Animals, Cell Division, Cell Movement, Diabetes Mellitus, Type 1, Female, Flow Cytometry, Humans, Lymph Nodes, Lymphocyte Activation, Male, Organ Specificity, Signal Transduction, T-Lymphocyte Subsets, Mice, Inbred NOD, Receptors, Glucagon, Mice, Knockout, T-Lymphocytes, Regulatory, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.